CHAPTER 1 INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2 RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1. Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers & Opportunities
4.1.1. Rise in prevalence of chronic diseases and increase in applications of therapeutic plasma
exchange
4.1.2. Increase in intensive research and clinical trials coupled with the rapid increase in the
aging population
4.1.3. Increasing adoption of therapeutic plasma exchange in rare neurological, hematology,
and autoimmune disorders
4.2. Market Restraints
4.2.1. Availability of alternative treatments
4.2.2. Side effects involved in the treatments
CHAPTER 5 GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET – BY
INDICATION
5.1. Multiple Myeloma
5.2. Waldenstrom Macroglobulinemia
5.3. Hemolytic Uremic Syndrome
5.4. Anti-GBM Disease
5.5. Wegener’s Granulomatosis
5.6. Post-Renal Transplant Rejection
5.7. Familial Hypercholesterolemia
5.8. Anca-Associated Vasculitis
5.9. Guillain-Barré Syndrome
5.10. Chronic Inflammatory Demyelinating Polyneuropathy
5.11. Myasthenia Gravis
5.12. Multiple Sclerosis
5.13. Neuromyelitis Optica
5.14. Cryoglobulinemia
5.15. Thrombotic Thrombocytopenic Purpura
CHAPTER 6 GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET - BY
GEOGRAPHY
6.1. Introduction
6.2. North America
6.2.1. U.S.
6.2.2. Canada
6.2.3. Mexico
6.2.4. Costa Rica
6.3. South America
6.3.1. Brazil
6.3.2. Argentina
6.3.3. Chile
6.3.4. Columbia
6.3.5. Others
6.4. Europe
6.4.1. U.K.
6.4.2. Germany
6.4.3. France
6.4.4. Italy
6.4.5. Spain
6.4.6. Russia
6.4.7. Netherlands
6.4.8. Switzerland
6.4.9. Poland
6.4.10. Others
6.5. APAC
6.5.1. China
6.5.2. Japan
6.5.3. India
6.5.4. South Korea
6.5.5. Australia & New Zealand
6.5.6. Malaysia
6.5.7. Singapore
6.5.8. Others
6.6. Middle East & Africa
6.6.1. UAE
6.6.2. Saudi Arabia
6.6.3. Iran
6.6.4. Iraq
6.6.5. Qatar
6.6.6. South Africa
6.6.7. Algeria
6.6.8. Morocco
6.6.9. Nigeria
6.6.10. Egypt
6.6.11. Others
CHAPTER 7 GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET -
COMPANY PROFILES
7.1. Terumo BCT, Inc.
7.2. Haemonetics Corporation
7.3. Kawasumi Laboratories, Inc.
7.4. HemaCare Corporation
7.5. Fresenius SE & Co. KGaA
7.6. Asahi Kasei Medical Co., Ltd.
7.7. Baxter International, Inc.
7.8. B. Braun Melsungen AG
7.9. Medica S.p.A.
7.10. Cerus Corporation
CHAPTER 8 GLOBAL THERAPEUTIC PLASMA EXCHANGE MARKET –
COMPETITIVE LANDSCAPE
8.1. Market Share Analysis
8.2. Strategies adopted by top companies
8.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 9 MARKET INSIGHTS
9.1. Industry Experts Insights
9.2. Analysts Opinions
9.3. Investment Opportunities
CHAPTER 10 APPENDIX
10.1. List of Tables
10.2. List of Figures
